Clinical trial NCT06979765: Research for Plasma Biomarkers Associated With Fatigue in Thrombocytopenic Patients
Official title: Research for Plasma Biomarkers Associated With Fatigue in Thrombocytopenic Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Thrombopenia
Keywords: Thrombopenia
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2025-05-20
Enrollment: 280
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Thrombocytopenia is a clinical problem defined by a platelet count lower than 150×10⁹/L. It can be linked to various pathologies of central origin, such as decreased platelet production in the bone marrow, or peripheral origin with increased platelet destruction through autoimmune mechanisms, increased splenic sequestration, or excessive platelet consumption. Significant fatigue is often reported in association with thrombocytopenia, but its underlying pathophysiology remains unclear. One hypothesis is the role played by neurotrophic factors contained in platelets and released into the circulation following their activation, in particular the Brain-Derived Neurotrophic Factor (BDNF), which promotes the survival, growth, differentiation, and plasticity of neurons in both the central and peripheral nervous systems. Consequently, BDNF plays a key role in long-term memory, intellectual abilities, and neuroprotection.

In this context, this project aims to confirm whether platelet-origin neurotrophic biomarkers could explain the fatigue experienced by thrombocytopenic patients and whether it depends on the etiology of the thrombocytopenia.

Detailed description: Thrombocytopenia is defined as a platelet count below 150×109/L. The mechanisms leading to thrombocytopenia are multiple, and may be linked to :

* reduced platelet production in the bone marrow;
* increased destruction of peripheral platelets;
* increased splenic sequestration. In the event of a vascular breach, platelets contribute to hemostasis by sealing the lesion, thereby stopping bleeding. In thrombocytopenic patients, the best-known clinical signs are excessive mucocutaneous bleeding. Patients with severe thrombocytopenia (\< 20×109 /L) may be at risk of life-threatening bleeding (cerebral bleeding).

In the case of autoimmune thrombocytopenia, cognitive disorders have been reported, detected by appropriate questionnaires, the pathophysiological mechanism of which remains unclear. In a study of 1871 patients with thrombocytopenia, 39% of patients in the UK and 22% in the USA reported severe asthenia. Asthenia appears to be related to thrombocytopenia, but the mechanism has not been identified either. Asthenia is a recognized symptom in other autoimmune pathologies, such as primary biliary cirrhosis (autoimmune liver disease), in which asthenia has been shown to be mainly associated with autonomic nervous system dysfunction.

While thrombocytopenia is primarily associated with bleeding risk, at least half of thrombocytopenic patients report fatigue and impaired mental and emotional health and social functioning, even though anemia is corrected and the association with autoimmune disease does not explain fatigue in all thrombocytopenic patients.

The hypothesis is that thrombocytopenia is associated with a decrease in circulating neurotrophic factor levels through reduced platelet granule secretion, which may explain the fatigue.

Eligibility criteria: Inclusion criteria for patients (adults or minors):

* Patients with constitutional or autoimmune (chronic or persistent ITP with last treatment administration ≥ 3 weeks) thrombocytopenia (platelet count \< 150×109/L) already diagnosed
* patient not being treated and not receiving serotonin reuptake inhibitor (SSRI) or norepinephrine (SNRI) or antithrombotic treatments (antiplatelet or anticoagulant) in the 10 days prior to inclusion
* affiliation to social security (beneficiary or assignee)
* patient followed in consultation in one of the recruiting haematology departments
* Patient (or parent) having received a detailed explanation of the research project and having consent by signing the consent form before any research-specific procedure

Inclusion criteria for healthy volunteers:

* Age- (± 5 years) and sex-matched healthy adult controls
* Non-thrombocytopenic patients and not receiving antithrombotic, SNRI or SSRI therapy or if applicable, last treatment ≥ 10 days
* affiliation to social security (beneficiary or assignee)
* adults who received a detailed explanation of the research project and having consent by signing the consent form before any research-specific procedure

Non inclusion criteria (adults and minors):

* Adult patients under legal protection (guardianship or curatorship) Thrombocytopenic patients treated with antithrombotics, serotonin reuptake inhibitors (SSRIs) or noradrenaline reuptake inhibitors (SNRIs)
* Minor patients weighing less than 20 kg

Non inclusion criteria for healthy adult controls:

* Healthy adult volunteers under legal protection (guardianship, curatorship or safeguard of justice).
* Pregnant women

Primary outcomes:
measure: Blood BDNF levels in thrombocytopenic adult and pediatric patients
timeFrame: At the inclusion
measure: Fatigue questionnaire scores for adult and pediatric patients
timeFrame: At the inclusion
measure: BDNF blood level in Healthy volunteers
timeFrame: At the inclusion
Secondary outcomes:
measure: Measurement of pro-BDNF blood level in thrombopenic adult and pediatric patients
timeFrame: At the inclusion
measure: measurement of p75NTR blood level in thrombopenic adult and pediatric patients
timeFrame: At the inclusion
measure: measurement of TrkB blood level in thrombopenic adult and pediatric patients
timeFrame: At the inclusion
measure: measurement of MMP9 blood level in thrombopenic adult and pediatric patients
timeFrame: At the inclusion
measure: measurement of Serotonin blood level in thrombopenic adult and pediatric patients
timeFrame: At the inclusion
measure: measurement of Dopamin blood level in thrombopenic adult and pediatric patients
timeFrame: At the inclusion
measure: measurement of P-selectin blood level in thrombopenic adult and pediatric patients
timeFrame: At the inclusion
measure: measurement of CD40 ligand blood level in thrombopenic adult and pediatric patients
timeFrame: At the inclusion
measure: anxiety questionnaire sub score of adult and pediatric patients
timeFrame: At the inclusion
measure: Depression questionnaire sub score of adult and pediatric patients
timeFrame: At the inclusion
measure: cognition questionnaire sub score of adult and pediatric patients
timeFrame: At the inclusion
measure: measurement of pro-BDNF blood level in Healthy volunteers
timeFrame: At the inclusion
measure: measurement of p75NTR blood level in Healthy volunteers
timeFrame: At the inclusion
measure: measurement of TrkB blood level in Healthy volunteers
timeFrame: At the inclusion
measure: measurement of MMP9 blood level in Healthy volunteers
timeFrame: At the inclusion
measure: measurement of Serotonin blood level in Healthy volunteers
timeFrame: At the inclusion
measure: measurement of Dopamin blood level in Healthy volunteers
timeFrame: At the inclusion
measure: measurement of P-selectin blood level in Healthy volunteers
timeFrame: At the inclusion
measure: measurement of CD40 ligand blood level in Healthy volunteers
timeFrame: At the inclusion
measure: anxiety questionnaire sub score in Healthy volunteers
timeFrame: At the inclusion
measure: Depression questionnaire sub score in Healthy volunteers
timeFrame: At the inclusion
measure: cognition questionnaire sub score in Healthy volunteers
timeFrame: At the inclusion
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital Bichat-Claude Bernard
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Nadine Ajzenberg
role: PRINCIPAL_INVESTIGATOR
References: